GalleonBio

Galleon Pharmaceuticals was a clinical-stage biotechnology company focused on the discovery and development of novel small molecule medicines for breathing control disorders. The company's research centered on the carotid body chemoreceptors, which play a vital role in regulating respiratory drive. Its lead clinical candidate, GAL-021, was an intravenous BK channel blocker designed to prevent or treat respiratory depression caused by opioids or anesthetics without diminishing pain relief. Galleon also advanced programs for sleep apnea, aiming to provide pharmacological alternatives to mechanical devices like CPAP. The company was acquired by Teva Pharmaceutical Industries in 2014 to strengthen its respiratory and pain management pipeline.